Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lactobacillus rhamnosus GG for Vernal Keratoconjunctivitis Relapse Prevention
NCT00445120Phase 3Completed
- Sponsor
- Università Campus Bio-Medico di Roma
- Start
- Mar 2007
- Primary completion
- Sep 2008
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Lactobacillus rhamnosus GG in Vernal Keratoconjunctivitis (VKC), sponsored by Università Campus Bio-Medico di Roma. Primary endpoint: Number of relapses of ocular inflammation at 2 years. Started Mar 2007; status: completed.
02
Drugs
Lactobacillus rhamnosus GG
03
Conditions
Vernal Keratoconjunctivitis (VKC)
Beyond the preview
Go deeper on NCT00445120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00445120.